SCHEMBL1950276

SCHEMBL1950276

O=C(CO)N1CCc2cc(NCc3ccc(Cl)cc3)ccc2C1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.52
TDP1 Q9NUW8 1/20 0.52
TMPRSS2 O15393 3/20 0.49
MEN1 O00255 2/20 0.46
GAA P10253 1/20 0.46
HSD17B3 P37058 1/20 0.45
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
ERCC1 P07992 1/20 0.42
ERCC4 Q92889 1/20 0.42
POLB P06746 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
HDAC1 Q13547 1/20 0.41
FFAR1 O14842 1/20 0.41
KCNA1 Q09470 1/20 0.41
KCNAB1 Q14722 1/20 0.41
WEE1 P30291 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1950717 0.90 KMT2A (0.49) KMT2ATDP1TMPRSS2MEN1GAA
SCHEMBL14871648 0.87 HSD17B3 (0.54) KMT2ATDP1TMPRSS2MEN1GAA
SCHEMBL1951535 0.87 KMT2A (0.48) KMT2ATDP1TMPRSS2MEN1GAA
SCHEMBL14871702 0.85 KDM4E (0.60) KMT2ATDP1TMPRSS2MEN1GAA
SCHEMBL2641070 0.84 KMT2A (0.39) KMT2ATDP1TMPRSS2MEN1GAA
SCHEMBL20537054 0.83 KMT2A (0.57) KMT2ATDP1TMPRSS2MEN1LMNA
SCHEMBL1948364 0.82 ESR2 (0.60) KMT2ATDP1TMPRSS2MEN1GAA
SCHEMBL20536418 0.79 HSD17B3 (0.57) KMT2ATMPRSS2MEN1HSD17B3NPC1
SCHEMBL20537078 0.76 HSD17B3 (0.53) KMT2ATDP1TMPRSS2MEN1GAA
SCHEMBL20537300 0.75 SMN1; SMN2 (0.53) KMT2ATDP1TMPRSS2MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2438055-B1 DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS JAPAN TOBACCO INC (JP) 2018-10-24 EP claimed
US-8426442-B2 Compounds XENTION LTD (GB) 2013-04-23 US claimed
EP-2438055-B1 DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS JAPAN TOBACCO INC (JP) 2018-10-24 EP disclosed
US-8426442-B2 Compounds XENTION LTD (GB) 2013-04-23 US disclosed
US-20110136860-A1 Compounds XENTION LTD. (GB) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136860-A1 Compounds NR3C2, NR5A1, NR0B2 KMT2A 2579/4885TDP1 3093/4885TMPRSS2 3043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.